FY2025 · ended Mar 31, 2026 · Revenue $8.26M, -71.6% YoY · Filed May 20, 2026
Roivant Sciences Ltd. (ROIV) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Mar 31, 2026, it reported revenue of $8.3 million and a net loss of $299.8 million. Free cash flow was -$758.6 million. As of Jun 30, 2026 it held $3.8 billion in cash and investments and $107.2 million in total debt.
Revenue (TTM)
$7.53M
-67.6% vs year-ago TTM
Net income (TTM)
$-266.25M
+45.7% vs year-ago TTM
Operating cash flow (TTM)
$-816.47M
+4.1% vs year-ago TTM
Free cash flow (TTM)
$-821.06M
+4.4% vs year-ago TTM
EPS (TTM)
$-0.38
+46.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
719.27M
+5.8% vs prior year
Net cash
$3.73B
as of Jun 30, 2026
Operating margin
-7914.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ROIV (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Bermuda
- Headquarters
- London
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1635088
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Mar 31, 2026 |
FY 2024 Mar 31, 2025 |
FY 2023 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Operating income | -$515.1M | -$1.0B | $4.5B | -$906.8M | -$1.4B |
| Net income | -$299.8M | -$172.0M | $4.3B | -$1.0B | -$845.3M |
| Diluted EPS | -$0.54 | -$0.24 | $5.23 | -$1.42 | — |
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M | -$695.2M |
| Total assets | $5.7B | $5.4B | $7.2B | $2.4B | $2.6B |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M |
| Stockholders' equity | $4.5B | $4.7B | $6.0B | $1.2B | $1.7B |
| Cash and investments | $4.3B | $4.9B | $6.5B | $1.7B | $2.1B |
| Total debt | $107.4M | $100.2M | $487.7M | $446.3M | $283.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Other events
|
Aug 28, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 27, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 995 Roivant Sciences Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.